Search
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].
Bazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIt is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … the prevention of postmenopausal osteoporosis in women.
Mixtures: DUAVIVE 20 mg/0.45 mg modified - release tablets, DUAVİVE 0.45 MG/20 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 TABLETTrichlormethiazide
go.drugbank.com/drugs/DB01021ApprovedVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigationalIt is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. … [L12771] It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate
Products: ARZERRA 100 MG I.V. İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (3 ADET), ARZERRA 1000 MG I.V. İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (1 ADET)Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test. … [L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common
Taurine
go.drugbank.com/drugs/DB01956ApprovedInvestigationalNutraceuticalTaurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. … [A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat.
Mixtures: SMOFKABIVEN EF, Numeta G 13 % E Emulsion zur InfusionIopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnOn September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.
Categories: Compounds used in a research, industrial, or household settingAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … [A263386] Patients with resistant hypertension are at an increased risk of cardiovascular and renal events[A263386] and have traditionally had limited additional treatment options.
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. … [A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663]
Mixtures: RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MG, RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MGSynonyms: (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediaminePonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalFDA approved on December 14, 2012.
Products: ICLUSIG TABLET 45 MG, ICLUSIG TABLET 15 MG